(Updated - January 27, 2022 4:04 PM EST)

Oppenheimer analyst Matthew Biegler initiates coverage on Celularity (NASDAQ: CELU) with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE